Mer­ck opens Vir­ginia plant to sup­port UNICEF deal for HPV vac­cines

A con­struc­tion project built around ex­pand­ing the vac­cine man­u­fac­tur­ing ca­pa­bil­i­ties at a Mer­ck site in Elk­ton, VA, has been com­plet­ed. The up­grades will sup­port the com­pa­ny’s hu­man pa­pil­lo­mavirus vac­cine, Gar­dasil 9, once it gains re­view and ap­proval from reg­u­la­tors.

About 150 new jobs have been added to the site, as the lo­ca­tion is now 120,000 square feet larg­er.

“As we con­tin­ue to in­crease pro­duc­tion of our HPV vac­cines, we are pri­or­i­tiz­ing ac­cess in coun­tries with a high bur­den of dis­ease, in­clud­ing coun­tries el­i­gi­ble for sup­port from Gavi and UNICEF,” Priya Agraw­al, glob­al lead for HPV Vac­cines at Mer­ck, said. “Through our long-term agree­ment with UNICEF, we plan to pro­vide 91.5 mil­lion dos­es of our HPV vac­cines for use in Gavi-sup­port­ed coun­tries from 2021-2025, and we have of­fered ad­di­tion­al dos­es be­yond that agree­ment as need­ed to help meet grow­ing de­mand.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.